Lv1
30 积分 2023-02-19 加入
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
5天前
已完结
Dose-reduction of bevacizumab in atezolizumab plus bevacizumab therapy extends treatment duration with disease control in patients with hepatocellular carcinoma
13天前
已关闭
Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma
21天前
已完结
Prevalence and Prognostic Significance of the Presence of Esophageal Varices in Patients With Hepatocellular Carcinoma
23天前
已关闭
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma
23天前
已完结
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis
23天前
已完结
Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2?-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model
23天前
已关闭
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
23天前
已完结
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
23天前
已完结
皖公网安备34019202002308
